16/04/2024
The 2024 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines for clinically localised prostate cancer (PCa) provide comprehensive recommendations on screening, diagnosis, and treatment.
Based on a thorough review of new data from May 2020 to 2023, the guidelines emphasize a risk-adapted approach, advocating for personalized screening starting at age 50 and utilizing multiparametric magnetic resonance imaging to reduce unnecessary biopsies. Active surveillance is recommended for low-risk PCa, including selected favorable intermediate-risk cases, while various local therapies and hypofractionation are discussed for intermediate-risk patients. Additionally, patients with nodal involvement are advised on combined local treatment and long-term hormonal therapy.
The guidelines underscore the evolving nature of PCa management and highlight the importance of multidisciplinary care.
https://www.sciencedirect.com/science/article/abs/pii/S0302283824022541